Institution
Royal Devon and Exeter Hospital
Healthcare•Exeter, United Kingdom•
About: Royal Devon and Exeter Hospital is a healthcare organization based out in Exeter, United Kingdom. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 2282 authors who have published 2526 publications receiving 78866 citations. The organization is also known as: RD&E.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: These findings support immediate treatment with zoledronic acid in patients with newly diagnosed multiple myeloma, not only for prevention of skeletal-related events, but also for potential antimyeloma benefits.
504 citations
••
TL;DR: This guideline has been produced as the official statement of the European Thyroid Association guideline committee and indicates that targeted antenatal screening for thyroid function will miss a substantial percentage of women with thyroid dysfunction.
Abstract: This guideline has been produced as the official statement of the European Thyroid Association guideline committee. Subclinical hypothyroidism (SCH) in pregnancy is defined as a thyroid-stimulating hormone (TSH) level above the pregnancy-related reference range with a normal serum thyroxine concentration. Isolated hypothyroxinaemia (defined as a thyroxine level below the 2.5th centile of the pregnancy-related reference range with a normal TSH level) is also recognized in pregnancy. In the majority of SCH the cause is autoimmune thyroiditis but may also be due to iodine deficiency. The cause of isolated hypothyroxinaemia is usually not apparent, but iodine deficiency may be a factor. SCH and isolated hypothyroxinaemia are both associated with adverse obstetric outcomes. Levothyroxine therapy may ameliorate some of these with SCH but not in isolated hypothyroxinaemia. SCH and isolated hypothyroxinaemia are both associated with neuro-intellectual impairment of the child, but there is no evidence that maternal levothyroxine therapy improves this outcome. Targeted antenatal screening for thyroid function will miss a substantial percentage of women with thyroid dysfunction. In children SCH (serum TSH concentration >5.5-10 mU/l) normalizes in >70% and persists in the majority of the remaining patients over the subsequent 5 years, but rarely worsens. There is a lack of studies examining the impact of SCH on the neuropsychological development of children under the age of 3 years. In older children, the evidence for an association between SCH and impaired neuropsychological development is inconsistent. Good quality studies examining the effect of treatment of SCH in children are lacking.
492 citations
••
TL;DR: It is postulate that abnormalities of factor H may be involved in the etiology of HUS.
491 citations
••
TL;DR: The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome, and the methods used to evaluate severity are discussed.
474 citations
••
Institute of Cancer Research1, University of Leicester2, University of Dundee3, Royal Devon and Exeter Hospital4, St George's Hospital5, University Hospitals Bristol NHS Foundation Trust6, Newcastle upon Tyne Hospitals NHS Foundation Trust7, Guy's and St Thomas' NHS Foundation Trust8, Great Ormond Street Hospital9, St Mary's Hospital10, Aberdeen Royal Infirmary11, Queen's University Belfast12, Cambridge University Hospitals NHS Foundation Trust13, Western General Hospital14, University Hospital of Wales15, University of Oxford16, University of Southampton17, University of Cambridge18
TL;DR: It is shown that cells deficient in RAD51D are sensitive to treatment with a PARP inhibitor, suggesting a possible therapeutic approach for cancers arising in RAD 51D mutation carriers.
Abstract: Nazneen Rahman and colleagues show that germline inactivating mutations in RAD51D confer susceptibility to ovarian cancer. They further show that RAD51D-deficient cells are sensitive to PARP inhibition, suggesting a possible strategy for treating cancers arising in RAD51D mutation carriers.
473 citations
Authors
Showing all 2288 results
Name | H-index | Papers | Citations |
---|---|---|---|
Andrew T. Hattersley | 146 | 768 | 106949 |
Timothy M. Frayling | 133 | 500 | 100344 |
Gordon D.O. Lowe | 105 | 560 | 44327 |
Rod S Taylor | 104 | 524 | 39332 |
Sian Ellard | 97 | 636 | 36847 |
Zoltán Kutalik | 90 | 321 | 42901 |
Michael N. Weedon | 87 | 201 | 60701 |
Masud Husain | 81 | 398 | 25682 |
David Melzer | 80 | 328 | 33458 |
Jonathan Mill | 78 | 301 | 36343 |
A. John Camm | 76 | 368 | 49804 |
David Silver | 74 | 227 | 81103 |
Jason D. Warren | 73 | 384 | 20588 |
Nicholas J. Talbot | 71 | 240 | 29205 |
Andrew R. Wood | 70 | 214 | 36203 |